trending Market Intelligence /marketintelligence/en/news-insights/trending/p_cAanHs8zJNHg0b7B0rEA2 content esgSubNav
In This List

ImmunoGen plans common stock offering

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


ImmunoGen plans common stock offering

ImmunoGen Inc. plans to offer and sell 13 million common shares in an underwritten public offering.

The company plans to grant underwriters an option to buy up to an additional 15% of the shares offered.

Net proceeds will be used to fund the company's operations, including research and development activities, clinical trial activities, manufacturing and supply of drug substance and drug products, commercialization preparation, acquisitions of new technologies, capital expenditures and working capital.

Jefferies, Leerink Partners and RBC Capital Markets are acting as joint book-running managers for the proposed offering. Canaccord Genuity is acting as co-manager for the proposed offering.